First-in-class GIP antagonist for obesity enters Phase I trials
Helicore Biopharma has reported dosing the first participant in its Phase I study of HCR-188 for the treatment of obesity.
HCR-188 is a first-in-class monoclonal antibody (mAb) designed to bind to circulating glucose-dependent insulinotropic peptide (GIP) ligand, unlike antibodies that bind the GIP receptor (GIP receptor antagonists).
It is hoped that HCR-188 and conjugates in development may uniquely prevent GIP signalling in the brain, potentially restoring leptin sensitivity that may support increased satiety as well as reduced consumption and fat deposition.
“Initiating this first-in-human study for GIP ligand binding with HCR-188, our humanised monoclonal antibody, is a significant milestone in the development of GIP ligand binding as a new mechanism of action in obesity treatment,” said Gerrit Klaerner, President and CEO of Helicore. “While we do not expect to see efficacy signals for weight loss given the known time to onset of GIP antagonism, demonstrating the safety and tolerability of GIP ligand binders in this SAD/MAD study will establish the foundation for further advancement of our product portfolio.”
The Phase I trial is a single ascending dose (SAD) and multiple ascending dose (MAD) study in volunteers who are overweight or obese and who do not have diabetes mellitus.
In addition to safety and pharmacokinetics, the study will examine the effect of HCR-188 on its target (GIP) and on inflammatory and metabolic markers such as lipids and glucose, as well as hormones affecting glucose and lipid metabolism and caloric intake.
Based on the novel mechanism of action of HCR-188 as a monoclonal antibody binding GIP ligand, an observable effect on weight loss in the four-week MAD treatment period is not expected.
Top-line safety data are anticipated in the second half of 2025.
Diana Spencer, Senior Digital Content Editor, DDW
